Cost Is the Biggest Barrier to Iyuzeh Adherence

You've prescribed Iyuzeh (preservative-free Latanoprost) because your patient needs it — maybe they have BAK sensitivity, chronic ocular surface disease, or they're on multiple preserved drops. The clinical rationale is sound. But when your patient gets to the pharmacy and sees a price tag of $264–$350 for a 30-day supply, many will simply walk away.

Medication cost is the number one driver of non-adherence in glaucoma treatment, and brand-name ophthalmic medications like Iyuzeh are especially vulnerable. This guide outlines the savings programs, discount tools, and workflow strategies that can help your patients actually fill — and keep filling — their Iyuzeh prescriptions.

What Your Patients Are Paying

Understanding the cost landscape helps you anticipate barriers:

• Cash price (no insurance): $264–$350 for a 30-day supply (2.5 mL, 30 single-dose containers)
• With commercial insurance: Varies widely. Many plans require prior authorization and step therapy (generic Latanoprost first). Even with coverage, copays for a brand-name tier 3 or specialty drug can be $60–$150+/month.
• Medicare Part D: Coverage varies by plan. Manufacturer copay programs are not available for Medicare, Medicaid, or other federal/state healthcare programs.
• Generic Latanoprost for comparison: $10–$30/month — a fraction of the cost, which is why insurers push step therapy

The gap between $15 generic Latanoprost and $300+ Iyuzeh is where most cost conversations begin. Your patients need to understand that Iyuzeh is genuinely more expensive to manufacture (single-dose, preservative-free) and that savings programs exist to close the gap.

Manufacturer Savings Programs

Thea Pharma offers the most impactful savings vehicle for Iyuzeh through their PhilRx program. Here's what's available:

Copay Savings Card (Commercially Insured Patients)

• Cost to patient: As low as $60 for a 30-day supply or $120 for a 90-day supply
• Eligibility: Commercially insured patients only. Not valid for Medicare, Medicaid, Tricare, or other government programs.
• Enrollment: Patients can enroll at myiyuzehsavings.com or text 744-579
• Additional benefit: PhilRx provides free home delivery with automatic refill reminders, which also solves the pharmacy stocking problem

Cash Savings Program (Uninsured/Cash-Pay Patients)

• Cost to patient: $75 per fill
• Eligibility: Cash-pay patients without insurance coverage for Iyuzeh
• Enrollment: Same pathway — myiyuzehsavings.com or text 744-579

Prior Authorization Support

PhilRx also assists with the prior authorization process. When you prescribe Iyuzeh, PhilRx can work with your office to navigate the PA requirements, which reduces administrative burden on your staff. This is particularly valuable because most commercial plans require step therapy documentation (evidence that the patient tried generic Latanoprost and it was inadequate).

Provider tip: Document BAK sensitivity, ocular surface disease, or intolerance to preserved formulations clearly in the chart. This documentation is what gets PAs approved.

Coupon and Discount Cards

Beyond the manufacturer program, third-party discount tools can help patients who fall through the cracks:

• GoodRx — Compare pharmacy prices for Iyuzeh at goodrx.com. Discounts may reduce the cash price, though savings are less dramatic than the manufacturer program for this brand-name product.
• SingleCare — Another discount card option. Check singlecare.com/prescription/iyuzeh for current pricing.
• RxSaver, BuzzRx, Optum Perks — Additional coupon card platforms worth checking. Prices vary by pharmacy.

For most patients, the manufacturer's $75 cash program will beat third-party coupon cards. But it's worth checking — especially for patients who are hesitant to enroll in manufacturer programs.

For a comprehensive list of all savings options, direct patients to Medfinder's Iyuzeh savings guide.

Generic Alternatives and Therapeutic Substitution

Sometimes the most impactful cost intervention is reconsidering whether the patient truly needs brand Iyuzeh versus an alternative:

When Generic Latanoprost Is Sufficient

For patients without BAK sensitivity or significant ocular surface disease, generic preserved Latanoprost at $10–$30/month may be perfectly adequate. Not every patient who asks about Iyuzeh needs it — some have heard about it and assume newer means better.

BAK-Free Alternatives

If the clinical goal is a preservative-free or BAK-free prostaglandin analog and cost is a barrier, consider:

• Travatan Z (Travoprost) — BAK-free (preserved with SofZia). May have better insurance coverage than Iyuzeh in some formularies.
• Zioptan (Tafluprost) — Preservative-free prostaglandin analog in single-dose containers. Another option, though availability and cost vary.

Different Drug Class Entirely

For patients who can't tolerate any prostaglandin analog, consider:

• Rhopressa (Netarsudil) — Rho kinase inhibitor, different mechanism
• Vyzulta (Latanoprostene Bunod) — Dual-mechanism, but contains BAK
• SLT (Selective Laser Trabeculoplasty) — Laser-based IOP reduction that eliminates the need for daily drops altogether

For a detailed comparison of alternatives, see our article on alternatives to Iyuzeh.

Building Cost Conversations into Your Workflow

Cost shouldn't be an afterthought — it should be part of the prescribing decision. Here are practical ways to build it into your practice:

At the Point of Prescribing

• Mention cost proactively. Don't wait for the patient to get sticker shock at the pharmacy. Say: "Iyuzeh retails for about $300/month, but there are programs that can bring it down to $60–$75. Let me give you the information."
• Provide the PhilRx enrollment info. Hand out a card or printed slip with myiyuzehsavings.com and the text number 744-579. Better yet, have your staff help patients enroll before they leave the office.
• Document the clinical rationale. Chart notes should clearly state why Iyuzeh is medically necessary (BAK sensitivity, ocular surface disease, failed trial of preserved Latanoprost). This speeds up prior authorization.

During Follow-Up Visits

• Ask about adherence. "Are you using Iyuzeh every evening?" If the answer is no, cost is often the reason.
• Check if they're using savings programs. Many patients forget to enroll or didn't understand the instructions. A quick check can save the prescription.
• Revisit the drug choice. If a patient is struggling with Iyuzeh costs despite savings programs, it may be time to discuss alternatives.

Staff Training

• Train your front desk and technicians to provide PhilRx enrollment information when Iyuzeh is prescribed
• Keep printed materials about Iyuzeh savings programs in exam rooms
• Designate a staff member to assist with prior authorization follow-up

Helping Patients Find Iyuzeh in Stock

Cost isn't the only barrier — availability is too. Iyuzeh is a newer specialty medication that many retail pharmacies don't routinely stock. When patients can't find it, they give up.

Point patients to Medfinder for Providers — a tool that helps locate pharmacies with Iyuzeh in stock. You can also recommend the PhilRx home delivery option, which eliminates the pharmacy availability problem entirely.

For more on supporting patients with availability issues, see our provider's guide to helping patients find Iyuzeh.

Final Thoughts

Iyuzeh fills a genuine clinical need — preservative-free Latanoprost for the millions of glaucoma patients who use prostaglandin drops daily for decades. But at $264–$350/month cash price, cost will undermine adherence unless you actively address it.

The good news: between the manufacturer's copay card ($60/month for insured patients), cash program ($75/fill for uninsured), and PhilRx's home delivery with PA support, most patients can get Iyuzeh at an affordable price. Your role as a provider is to make sure patients know these options exist — ideally before they leave your office with a new prescription.

When cost conversations become part of your workflow rather than an afterthought, you'll see better adherence, better outcomes, and fewer patients silently abandoning their glaucoma treatment.